Functional adrenocortical carcinoma: Case report

被引:0
作者
Francisco Garcia-Carrazco, Cesar [1 ]
Ahmed Nacud-Bezies, Yamir [1 ]
Espinoza-Velazco, Absaln [1 ]
del Rosario Munoz-Ramirez, Maria [1 ]
Javier Rivera-Castillo, Enrique [1 ]
Ramon Marquez-Toscano, Jose [1 ]
机构
[1] UMAE, IMSS, Residente Cirug Digestiva & Endocrina, Monterrey, NL, Mexico
来源
GACETA MEXICANA DE ONCOLOGIA | 2012年 / 11卷 / 02期
关键词
Adrenocortical carcinoma; adrenalectomy; hypercorticism; Cushing's syndrome; Mexico;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The suprarrenal carcinoma is a rare disease. More than 60% of those tumors are functional: Cushing's syndrome (45%), Cushing and virilization (25%), virilization alone (10%, in children more than 85%). Nonfunctional tumors occur as incidentalomas in advanced age and have worse prognosis. It is diagnosed by CT o MRI. Functional tumors must to be show hypercortisolism. Potentially curative treatment is surgical resection. Advanced disease has poor response to mitotane and chemotherapy. Adrenal insufficiency post resection should be avoided with use of steroids. We present a female 34 year-old, whit morbid obesity (BMI: 55 kg/m(2)), hypertension, hypotiroidism, venous insufficiency and varicose ulcers, amenorrhea, hirsutism and dermatitis acneiform. Laboratories test detected hypercortisolism and an abdominal CT scan showed a giant left adrenal tumor. She underwent left adrenalectomy- nefrectomy, splenectomy and distal pancreatectomy. During postsurgical period developed acute kidney injury requiring hemodialysis, which exacerbate the postoperative adrenal insufficiency and died at the five day. It is important detect this condition in early stages due survival rates at 5 years are: Stage I 82%, Stage II 61%, Stage III 50% y Stage IV 13%. Without resection the survival rate is 6-9 months, even whit the use of mitotane; its main benefit is to decrease symptoms of hypercortisolism. Currently the survival has been improved with adequate surgical resection and adjuvant therapy whit mitotane and cytotoxic drugs.
引用
收藏
页码:118 / 122
页数:5
相关论文
共 26 条
[1]  
Baldras-Ariza J, 1998, REV MEX UROL, V58, P95
[2]   The molecular genetics of adrenocortical carcinoma [J].
Barlaskar, Ferdous M. ;
Hammer, Gary D. .
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2007, 8 (04) :343-348
[3]   Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial [J].
Berruti, A ;
Terzolo, M ;
Sperone, P ;
Pia, A ;
Della Casa, S ;
Gross, DJ ;
Carnaghi, C ;
Casali, P ;
Porpiglia, F ;
Mantero, F ;
Reimondo, G ;
Angeli, A ;
Dogliotti, L .
ENDOCRINE-RELATED CANCER, 2005, 12 (03) :657-666
[4]   Origin and Molecular Pathology of Adrenocortical Neoplasms [J].
Bielinska, M. ;
Parviainen, H. ;
Kiiveri, S. ;
Heikinheimo, M. ;
Wilson, D. B. .
VETERINARY PATHOLOGY, 2009, 46 (02) :194-210
[5]  
Castellano-Orozco M, 2009, REV MEX UROL, V69, P238
[6]   The Italian registry for adrenal cortical carcinoma: Analysis of a multiinstitutional series of 129 patients [J].
Crucitti, F ;
Bellantone, R ;
Ferrante, A ;
Boscherini, M ;
Crucitti, P ;
Carbone, G ;
Casaccia, M ;
Campisi, C ;
Cavallaro, A ;
Sapienza, P ;
DelGaudio, A ;
Solidoro, G ;
Dettori, G ;
Marogna, P ;
DiGiovanni, V ;
Colli, R ;
Doglietto, G ;
Gozzetti, G ;
Maldarizzi, F ;
Marrano, D ;
Minni, F ;
Masenti, E ;
Fronticelli, CM ;
Miccoli, P ;
Iacconi, P ;
Mosca, F ;
Roccella, M ;
Mussa, A ;
Sandrucci, S ;
Petronio, R ;
Valerio, A ;
Piat, G ;
Cangemi, V ;
Ruberti, U ;
Miani, S ;
Serio, G ;
Montresor, E ;
Zarrilli, L ;
Marzano, L .
SURGERY, 1996, 119 (02) :161-170
[7]   Clinical management of adrenocortical carcinoma [J].
Fassnacht, Martin ;
Allolio, Bruno .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (02) :273-289
[8]   Limited Prognostic Value of the 2004 International Union Against Cancer Staging Classification for Adrenocortical Carcinomas [J].
Fassnacht, Martin ;
Johanssen, Sarah ;
Quinkler, Marcus ;
Bucsky, Peter ;
Willenberg, Holger S. ;
Beuschlein, Felix ;
Terzolo, Massimo ;
Mueller, Hans-Helge ;
Hahner, Stefanie ;
Allolio, Bruno .
CANCER, 2009, 115 (02) :243-250
[9]   18F-Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Adrenocortical Tumors: A Prospective Study in 77 Operated Patients [J].
Groussin, Lionel ;
Bonardel, Gerald ;
Silvera, Stephane ;
Tissier, Frederique ;
Coste, Joel ;
Abiven, Gwenaelle ;
Libe, Rossella ;
Bienvenu, Marie ;
Alberini, Jean-Louis ;
Salenave, Sylvie ;
Bouchard, Philippe ;
Bertherat, Jerome ;
Dousset, Bertrand ;
Legmann, Paul ;
Richard, Bruno ;
Foehrenbach, Herve ;
Bertagna, Xavier ;
Tenenbaum, Florence .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (05) :1713-1722
[10]   Clinical utility of noncontrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland clinic experience [J].
Hamrahian, AH ;
Ioachimescu, AG ;
Remer, EM ;
Motta-Ramirez, G ;
Bogabathina, H ;
Levin, HS ;
Reddy, S ;
Gill, IS ;
Siperstein, A ;
Bravo, EL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (02) :871-877